The ratio of the pre-ejection period to the left ventricular ejection time (PEP:LVET) was measured in two groups of patients with acute myeloblastic leukaemia (AML) receiving the anthracycline antibiotic doxorubicin (DXR). Patients receiving high doses of DXR per course (about 90 mg/M2) showed a significant increase in the PEP:LVET ratio irrespective of the total cumulative dose. At a lower dose per course (less than 50 mg/m') only patients who had a total cumulative dose of over 450 mg/M2 showed significant increases in ratio. ECG changes were seen in both groups of patients but did not correlate significantly with the dosage. These findings, which suggest that DXR cardiotoxicity is schedule dependent, are important in the design of schedules of DXR for treating cancer and in interpreting the changes in systolic time intervals (STIs) observed with different schedules.
Introduction
The most effective treatments for acute myeloblastic leukaemia (AML) in adults are those that include the anthracycline antibiotics daunorubicin or doxorubicin (DXR).1 DXR is also extremely effective in the management of many solid tumours.2 Bone-marrow depression is the major short-term toxic effect,' others include nausea and vomiting, stomatitis, alopecia, and phlebitis at the injection site. DXR cardiotoxicity, which is related to the total cumulative dose, constitutes the major limiting factor when this valuable chemotherapeutic agent is used."-"
The clinical and laboratory features of DXR cardiomyopathy are those of congestive heart failure, the most striking characteristic being the rapidly progressive course., The condition may be controlled if diagnosed early and treated intensively, but monitoring the ECG, chest x-ray films, and cardiac enzyme concentrations is not helpful in predicting DXR cardiotoxicity.4 5 7 8Minow et al, 9 however, showed that a low QRS voltage was present at the onset of congestive heart failure, and they suggested that a reduction of 40% or more in the total absolute deflection of the QRS complex measured on the six limb leads when associated with any clinically detectable cardiac abnormality may be an indication to discontinue DXR treatment. Rinehart et (table II) . These patients were also receiving cytarabine with or without thioguanine. There was no significant difference in the total cumulative dose between the two groups. We also studied a control group of 10 patients, four with acute leukaemia, who were receiving chemotherapeutic agents other than anthracyclines (table III) . No patient in any of the groups had radiotherapy to the mediastinum or precordium. The patients' histories, clinical examina'. tion, ECG, and chest radiograph showed no evidence of cardiovascular disease. STIs were measured using a multichannel photographic system by simultaneously recording the ECG, phonocardiogram, and carotid pulse tracing.11 The PEP:LVET ratio and changes in PEP, LVET, and total electromechanical systole corrected for heart rate12-14 were used to evaluate left ventricular function. A chest x-ray film and standard 12-lead ECG were obtained for each patient at the time of measurement. These measurements were carried out before and three weeks after each course of treatment. If patients showed any appreciable change in the STI the measurements were repeated at two-weekly intervals.
Results

GROUP 1
Twelve of the 15 patients showed a significant (> 0 08) increase in the PEP:LVET ratio, the mean for the whole group being 0-14 ( The most common ECG changes observed in our patients were abnormalities in cardiac rhythm, particularly supraventricular and ventricular arrhythmias and non-specific ST-segment and T-wave abnormalities. These changes, however, were not specific, as they occurred at all cumulative doses, were unrelated to the dosage schedule, and did not necessarily recur after further injections of DXR. Most of the changes, particularly the ventricular and supraventricular premature beats, disappeared within a few hours.
Measurements of the absolute deflections of the QRS complex in the six limb leads as suggested by Minow et al were also carried out. In group 1 only the patient whose case report is presented above showed a decrease in the amplitude of more than 5000, the mean decrease for the group being 1000. These changes did not correlate significantly with the total cumulative dose of DXR. In group were then followed up. Seven of the eight patients who had a total cumulative dose of less than 450 mg/M2 did not show a significant change.
Measurement of the STI is a sensitive means of detecting myocardial injury induced by DXR. It should be emphasised that changes in the STI may subside weeks or months after stopping the drug, even in patients who may have a very high total -dose. These patients, however, remain at high risk of developing congestive heart failure if DXR is restarted, even up to two years after the last dose of the drug. We recommend, therefore, that a total dose of DXR of 550 mg/M2 should not be exceeded unless the benefit of achieving further remission outweighs the risk of cardiotoxicity. Carefully monitoring cardiac function by measuring the STI in these circumstances will aid the early detection of myocardial dysfunction. Finally, as the recommended total dose of DXR is relatively low, the drug is probably best reserved for induction treatment in patients with AML. This is especially important if modern induction protocols using relatively high doses per course are used. Maintenance chemotherapy may be carried out using noncardiotoxic agents known to be effective in this disease. 21 McDonald, I G, and Hobson, E R, American Heart Journal, 1974 Life-table analysis suggested that the incidence of CNS malformations is 16/1000 at the beginning of the eighth week of gestation. It was also estimated that only onefifth of these infants are born alive, 41% being aborted spontaneously and 38% stillborn. A hypothesis that differences in the incidence of CNS malformations result from area differences in the mortality rate of malformed embryos and fetuses was examined by comparing the findings in Northern Ireland, an area of high incidence, with those in south-east England, an area of low incidence. In Northern Ireland 4-6% of complete conceptuses had a CNS malformation compared with 3 0% in south-east England, but the difference was not statistically significant. There is no evidence that in Northern Ireland a lower mortality rate among malformed fetuses and embryos is responsible for the high incidence of malformation at birth. The geographical variation of CNS malformations in the United Kingdom still awaits explanation.
Introduction
In the United Kingdom the incidence of central nervous system (CNS) malformations shows a pronounced geographical gradient, which steadily increases from the south and east to the north and west; the incidence (per 1000 total births) in southeast England is 2-95,1 in Wales 7-6,2 and in Northern Ireland 8 6.3 This gradient has been confirmed by several other reliable studies. The ratio of the prevalence of spina bifida to anencephaly is relatively constant, with a slight excess of spina bifida. In a study of regional variation in incidence of these malformations at birth, Roberts and Lloyd4 found an inverse relation between previous spontaneous abortion rates and the prevalence at birth of CNS malformations. They hypothesised that there is little or no difference in the incidence of CNS defects shortly after conception and that the observed differences in the third trimester arise only because of a greater prenatal mortality rate among malformed embryos in areas of low incidence. This may be tested by examining spontaneously aborted fetuses from areas with high and low incidences of CNS malformations; if correct there should be "a higher proportion of aborted conceptuses with CNS defects in the area of low incide!ice.5 In south-east England
